Adjuvant therapy of biliary tract cancers.

Biliary tract cancers (BTCs) are rare and heterogeneous malignant tumours including cholangiocarcinoma and gallbladder cancer. They are very aggressive, often refractory to chemotherapy and associated with an overall poor prognosis. Surgical resection remains the only potentially curative treatment option but less than 35% present with resectable disease. Adjuvant treatments have been widely used but until recently, supportive data were limited to non-randomised, non-controlled retrospective studies. Recent evidence from the BILCAP trial has established adjuvant capecitabine as the standard of care. But there are still unanswered questions as to the role of adjuvant therapy. Further prospective data and translational research with reproducible evidence of clinical benefit are needed. In this review of adjuvant therapy in resectable BTCs, we will summarise the latest evidence setting current treatment standards and highlight future prospects.

Informations de copyright

© The Author(s), 2023.

Déclaration de conflit d'intérêts

J Bridgewater: Consulting or Advisory Role – Bayer, Bristol Myers Squibb, Roche, Incyte, Servier, Taiho; Institutional Funding – National Institute of Health Research. A Vogel: Consulting or Advisory role – AstraZeneca, Amgen, BeiGene, Böhringer Mannheim, BMS, BTG, Daichi-Sankyo, EISAI, Incyte, Ipsen, MSD, PierreFabre, Roche, Servier, Sirtex, Tahio, Terumo; Speaker – AstraZeneca, Amgen, BeiGene, Böhringer Mannheim, BMS, BTG, Daichi-Sankyo, EISAI, GSK, Imaging Equipment Ltd (AAA), Incyte, Ipsen, Jiangsu Hengrui Medicines MSD, PierreFabre, Roche, Servier, Sirtex, Tahio, Terumo; Research Funding – Servier, Incyte; Commercial medical education provider – Onclive, Oncowissen.des. A Stein: Advisory Board – AstraZeneca, Taiho; Funding – German Cancer Aid. J Primrose: Advisory Board – AstraZeneca. J Kefas has nothing to disclose.